CYP19A1 and breast carcinoma: While IL-6 treatment leads to aromatase activation in endometrial and breast cancers [18,19,20], in dermal fibroblasts, IL-6 and E2 increased CYP19A1 transcript levels (Figure 2), suggesting increased aromatase activation.